Drug Profile


Alternative Names: SB 223242; SB 223412; SB 223412A; Talnetant hydrochloride

Latest Information Update: 07 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia
  • Discontinued Chronic obstructive pulmonary disease; Cough; Irritable bowel syndrome; Overactive bladder; Urinary incontinence

Most Recent Events

  • 30 May 2007 Data presented at the Digestive Disease Week-2007 (DDW-2007) have been added to the Digestive system disorders therapeutic trials section ,
  • 14 May 2007 Talnetant is still in phase II trials for schizophrenia in the US
  • 15 Dec 2005 Discontinued - Phase-II for Irritable bowel syndrome in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top